Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $27.20 | Total: $136.00 |
| 1 | 10 | $23.04 | Total: $230.40 |
| 1 | 25 | $19.52 | Total: $488.00 |
| 1 | 50 | $16.64 | Total: $832.00 |
| 1 | 100 | $14.40 | Total: $1,440.00 |
Overview
Senaparib (IMP4297) is a novel highly potent and selective oral PARP12 inhibitor with strong antitumor activity.
Chemical Properties
| Molecular Formula | C24H20F2N6O3 |
| Molecular Weight | 478.45 |
| CAS Numbers | 1401682-78-7 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | Fc1ccc(Cn2c3cccc(F)c3c(=O)[nH]c2=O)cc1C(=O)N1CCN(CC1)c1ncccn1 |
Storage and Handling
0C Short Term, -20C Long Term
References
P. de Souza, et al. 574P Updated results of phase I study of senaparib [IMP4297] in Australian patients with advanced solid tumours. ABSTRACT ONLY